Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Superficial Ventral Premotor Pathways to Primary Motor Cortex Shape the Temporal Coordination of Precision Grasping.

The European journal of neuroscience·2026
Same author

Hippocampal-cortical structural networks in the progression of cognitive impairment: A source-based morphometry analysis in individuals with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease.

Neurobiology of aging·2026
Same author

Eating Disorder Risk Among Italian University Students: A Cross-Sectional Screening Study Using BMI, EAT-26, and EDE-Q 6.0.

Nutrients·2026
Same author

Shaping the cognitive reserve: the role of lifelong enrichment and education in the Alzheimer's disease continuum.

Frontiers in aging neuroscience·2026
Same author

Effects of combined cerebellar tACS-iTBS in individuals with ataxia (EtABeta): a crossover investigation.

Trials·2026
Same author

Disrupted intracortical inhibition in the prefrontal cortex relates to cognitive dysfunction in post-COVID-19 condition: A TMS-EEG study.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Lisa Fosdick1, Giacomo Koch1,2

  • 1Sinaptica Therapeutics, Cambridge, MA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括

这项研究研究了阿尔茨海默病 (AD) 默认模式网络 (nDMN) 的神经调节. RETAIN试验旨在评估nDMN是否是对轻度至中度AD患者的安全和有效治疗.

科学领域:

  • 神经科学是一个神经科学.
  • 神经学 神经学
  • 临床试验 临床试验

背景情况:

  • 改变皮质可塑性是阿尔茨海默病 (AD) 的标志.
  • 非侵入性脑刺激提供了一种潜在的治疗方法,以恢复皮质可塑性和突触活动.
  • 之前的试验确定了默认模式网络 (nDMN) 神经调制对轻度至中度AD的安全性和可行性.

研究的目的:

  • 评估nDMN在患有轻度至中度AD的患者的疗效和安全性.
  • 探索nDMN作为AD治疗方式的作用机制.
  • 作为一个关键试验,支持向FDA提交De Novo分类请求.

主要方法:

  • 未来的,多中心,双盲,随机对照试验 (RETAIN试验).
  • 包括患有轻度至中度AD (4-5期,CDR0.5-2.0) 的患者,具有积极的生物标志物和最近的记忆力下降.
  • 治疗包括10天的启动和每周22次通过Sinaptistim系统的nDMN,使用TMS-EEG进行个性化目标/强度选择;积极治疗 (2/3) 与假药 (1/3).

主要成果:

  • 将使用认知和功能测量 (ADAS-Cog13,ADCS-ADL,CDR) 来评估有效性.
  • 将分析神经成像 (MRI,fMRI) 和神经退行和突触活动的血生物标志物.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451
  • 该研究的设计采用无可适应的P2/P3设计,并进行临时分析以调整样本大小 (至少120名参与者).
  • 结论:

    • RETAIN试验旨在确定nDMN对轻度至中度AD的疗效和安全性.
    • 部分研究和探索性分析将进一步调查治疗的作用机制.
    • 该试验的结果旨在支持FDA的De Novo分类请求.